Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (697)	6/9/1999 5:38:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 4974

I'd bet that, if enough reporters pick up on today's FDA/Merck "anti-Pfizer" thread (and investigate it in depth), a single day's lasting impression could cost Pfizer a bundle. Not to imply that the impression would hold up over time.

To: scaram(o)uche who wrote (697)	6/9/1999 5:51:00 PM
From: Biomaven	Read Replies (1) \| Respond to of 4974

But, aren't they being approved without the desired gut labeling? FDA just being ultra-conservative. Trials basically showed same ulcer rate on endoscopy as placebo, but the FDA kept a weakened version of the old NSAID warning. Celebrex is around $2 a dose, or $4 a day. Supposed to be comparable to existing patent-protected NSAIDS, but obviously much more than the generics. Peter